Contraindications to metformin therapy among patients with type 2 diabetes mellitus
- 236 Downloads
The biguanide, metformin, is a commonly prescribed oral antihyperglycemic agent. However, there are several clinical conditions that are considered as contraindications to the use of metformin among patients with type 2 diabetes mellitus. The aim of this study was to investigate the presence and nature of contraindications to metformin therapy among patients with type 2 diabetes mellitus.
A retrospective study of the medical files of diabetic patients available at Alwosta clinic, north Palestine was carried out. Information about disease and medication profile of the patients was retrieved and analyzed using SPSS during the study period in 2004/2005. Focus was on metformin users who have contraindications to metfromin therapy.
Main outcome measure
Presence and number of contraindications to metformin therapy.
Two hundred and seventy-two type 2 diabetic patients were identified. One hundred and twenty four of those diabetic patients were metformin users. Approximately, 60% of patients in the metformin group had a least one contraindication. Congestive heart failure and renal impairment were the most quantitatively present contraindications.
Contraindications to metformin therapy are common among type 2 diabetic patients and mostly disregarded. Patients have to be critically assessed before starting therapy and in case of metformin prescribing; dose should be adjusted based on the presence of risk factors for metformin adverse effects.
KeywordsContraindications Drug-related problems Medication-related problems Medication safety Metformin Palestine Type 2 diabetes mellitus
The author is very grateful for the Palestinian Ministry of Health for all the support that they have given in order to complete this project. The author would like also to specially thank Dr. Ola Aker for her help in the clinics.
- 1.Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27 Suppl 2:S1–152. Available: www.diabetes.ca/cpg2003/chapters.aspxGoogle Scholar
- 3.DeFronzo RA, Goodman AM & the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541–9.Google Scholar
- 4.Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;237:25–33.Google Scholar
- 5.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65, 1557.Google Scholar
- 11.Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia. 2005;48(12):2454–9. Epub 2005 Nov 11.Google Scholar
- 16.Bristol-Meyers Squibb. Prescribing information for glucophage. Princeton, New Jersey, November 14, 1997.Google Scholar
- 20.Chan NN, Fauvel NJ, Feher MD. Non-steroidal anti-inflammatory drugs and metformin: a cause for concern? Lancet 1998;352:201.Google Scholar
- 21.Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967. Review.Google Scholar